Lucid Capital initiated coverage of Cassava Sciences (SAVA) with a Buy rating and $8 price target Cassava is developing simufilam to treat a drug-resistant epilepsy, tuberous sclerosis, the analyst tells investors in a research note. The firm sees blockbuster potential for the drug.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAVA:
- Insider Moves: Cassava, Lithium Americas, EOG, Seagate, Pure Storage
- Cassava, Celestica, Gitlab, Pure, Stag: Stock Moves
- Cassava Sciences (SAVA) Insider Trade Alert! CEO Richard Barry Buys Stock
- Cassava Sciences Releases New Corporate Presentation
- Cassava Sciences Advances Simufilam for Epilepsy Treatment